Therefore, evaluation of biologics, such as the anti‐integrin vedolizumab, for indications of inflammatory diseases including IBD is recommended to determine their potential to affect CYP substrates through cytokine modulation. This evidence concerns the gene PPIG and inflammatory bowel disease.